Cargando…

Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children

The incidence and prevalence rate of chronic inflammatory disorders is on the rise in the pediatric population. Recent research indicates the crucial role of interactions between the altered intestinal microbiome and the immune system in the pathogenesis of several chronic inflammatory disorders in...

Descripción completa

Detalles Bibliográficos
Autores principales: Torun, Anna, Hupalowska, Anna, Trzonkowski, Piotr, Kierkus, Jaroslaw, Pyrzynska, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215716/
https://www.ncbi.nlm.nih.gov/pubmed/34163468
http://dx.doi.org/10.3389/fimmu.2021.642166
_version_ 1783710295614554112
author Torun, Anna
Hupalowska, Anna
Trzonkowski, Piotr
Kierkus, Jaroslaw
Pyrzynska, Beata
author_facet Torun, Anna
Hupalowska, Anna
Trzonkowski, Piotr
Kierkus, Jaroslaw
Pyrzynska, Beata
author_sort Torun, Anna
collection PubMed
description The incidence and prevalence rate of chronic inflammatory disorders is on the rise in the pediatric population. Recent research indicates the crucial role of interactions between the altered intestinal microbiome and the immune system in the pathogenesis of several chronic inflammatory disorders in children, such as inflammatory bowel disease (IBD) and autoimmune diseases, such as type 1 diabetes mellitus (T1DM) and celiac disease (CeD). Here, we review recent knowledge concerning the pathogenic mechanisms underlying these disorders, and summarize the facts suggesting that the initiation and progression of IBD, T1DM, and CeD can be partially attributed to disturbances in the patterns of composition and abundance of the gut microbiota. The standard available therapies for chronic inflammatory disorders in children largely aim to treat symptoms. Although constant efforts are being made to maximize the quality of life for children in the long-term, sustained improvements are still difficult to achieve. Additional challenges are the changing physiology associated with growth and development of children, a population that is particularly susceptible to medication-related adverse effects. In this review, we explore new promising therapeutic approaches aimed at modulation of either gut microbiota or the activity of the immune system to induce a long-lasting remission of chronic inflammatory disorders. Recent preclinical studies and clinical trials have evaluated new approaches, for instance the adoptive transfer of immune cells, with genetically engineered regulatory T cells expressing antigen-specific chimeric antigen receptors. These approaches have revolutionized cancer treatments and have the potential for the protection of high-risk children from developing autoimmune diseases and effective management of inflammatory disorders. The review also focuses on the findings of studies that indicate that the responses to a variety of immunotherapies can be enhanced by strategic manipulation of gut microbiota, thus emphasizing on the importance of proper interaction between the gut microbiota and immune system for sustained health benefits and improvement of the quality of life of pediatric patients.
format Online
Article
Text
id pubmed-8215716
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82157162021-06-22 Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children Torun, Anna Hupalowska, Anna Trzonkowski, Piotr Kierkus, Jaroslaw Pyrzynska, Beata Front Immunol Immunology The incidence and prevalence rate of chronic inflammatory disorders is on the rise in the pediatric population. Recent research indicates the crucial role of interactions between the altered intestinal microbiome and the immune system in the pathogenesis of several chronic inflammatory disorders in children, such as inflammatory bowel disease (IBD) and autoimmune diseases, such as type 1 diabetes mellitus (T1DM) and celiac disease (CeD). Here, we review recent knowledge concerning the pathogenic mechanisms underlying these disorders, and summarize the facts suggesting that the initiation and progression of IBD, T1DM, and CeD can be partially attributed to disturbances in the patterns of composition and abundance of the gut microbiota. The standard available therapies for chronic inflammatory disorders in children largely aim to treat symptoms. Although constant efforts are being made to maximize the quality of life for children in the long-term, sustained improvements are still difficult to achieve. Additional challenges are the changing physiology associated with growth and development of children, a population that is particularly susceptible to medication-related adverse effects. In this review, we explore new promising therapeutic approaches aimed at modulation of either gut microbiota or the activity of the immune system to induce a long-lasting remission of chronic inflammatory disorders. Recent preclinical studies and clinical trials have evaluated new approaches, for instance the adoptive transfer of immune cells, with genetically engineered regulatory T cells expressing antigen-specific chimeric antigen receptors. These approaches have revolutionized cancer treatments and have the potential for the protection of high-risk children from developing autoimmune diseases and effective management of inflammatory disorders. The review also focuses on the findings of studies that indicate that the responses to a variety of immunotherapies can be enhanced by strategic manipulation of gut microbiota, thus emphasizing on the importance of proper interaction between the gut microbiota and immune system for sustained health benefits and improvement of the quality of life of pediatric patients. Frontiers Media S.A. 2021-06-07 /pmc/articles/PMC8215716/ /pubmed/34163468 http://dx.doi.org/10.3389/fimmu.2021.642166 Text en Copyright © 2021 Torun, Hupalowska, Trzonkowski, Kierkus and Pyrzynska https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Torun, Anna
Hupalowska, Anna
Trzonkowski, Piotr
Kierkus, Jaroslaw
Pyrzynska, Beata
Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
title Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
title_full Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
title_fullStr Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
title_full_unstemmed Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
title_short Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
title_sort intestinal microbiota in common chronic inflammatory disorders affecting children
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215716/
https://www.ncbi.nlm.nih.gov/pubmed/34163468
http://dx.doi.org/10.3389/fimmu.2021.642166
work_keys_str_mv AT torunanna intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren
AT hupalowskaanna intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren
AT trzonkowskipiotr intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren
AT kierkusjaroslaw intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren
AT pyrzynskabeata intestinalmicrobiotaincommonchronicinflammatorydisordersaffectingchildren